RxDoctor Payments Data

John Baron, DO

Nephrology · Travis Afb, CANPI 1861471591

Payments from drug & device makers

$6,039in general payments, 2019–2025

Across 123 payments — averaging $49.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$4K
  • AstraZeneca$810
  • Vifor Pharma, Inc.$241
  • Calliditas Therapeutics US Inc.$197
  • Amgen$172
  • Fresenius USA Marketing, Inc.$124
  • plus $920 from 17 others

What the payments were for

  • Consulting fees$3,03750%
  • Food & beverage$2,98249%
  • Education$200%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,039 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$301,610
Medicare patients
605
Services billed
2,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol334$464,500
JardianceEmpagliflozin189$249,230
KerendiaFinerenone88$127,828
OzempicSemaglutide74$99,946
VeltassaPatiromer Calcium Sorbitex13$34,268
DapagliflozinDapagliflozin Propanediol29$19,677
LokelmaSodium Zirconium Cyclosilicate12$19,189
Losartan Potassium196$1,580
Amlodipine Besylate230$1,539
Bumetanide19$1,225
Furosemide127$1,043
Valsartan20$894
Chlorthalidone58$698
Carvedilol100$656
Nifedipine ErNifedipine15$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$810$483,689346 claims
Boehringer IngelheimJardiance$59$249,230189 claims
BayerKerendia$3,575$127,82888 claims
Novo NordiskOzempic$79$99,94674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.

Other nephrology in Travis Afb

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →